Picture of Maravai Lifesciences Holdings logo

MRVI — Maravai Lifesciences Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Maravai LifeSciences Holdings Inc expected to post earnings of 44  cents a share - Earnings Preview

* Maravai LifeSciences Holdings Inc  MRVI.OQ   MRVI.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 5. 
    * The San Diego California-based  company is expected to
report  a
56.7% increase in revenue to $232.299 million from $148.21
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Maravai
LifeSciences
Holdings Inc is for earnings of 44 cents per share. For the same
quarter last year, the company reported earnings of 26 cents per
share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Maravai
LifeSciences Holdings Inc is $46​, above​ its last closing price
of $30.13. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  0.38        0.38       0.45      Beat    17.1
 Sep. 30 2021  0.36        0.35       0.44      Beat    24.9
 Jun. 30 2021  0.32        0.32       0.44      Beat    39​
 Mar. 31 2021  0.21        0.21       0.26      Beat    26.6
 ​​Dec.        0.11        0.11       0.13      Beat    20.3
 31 2020                                                
                                                        ​
 This summary was machine generated May 4 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Maravai Lifesciences Holdings

See all news